Over the last 9 months, Snowdome’s funding efforts have been concentrated on directing just over $1,000,000 into epigenetic treatments for Australians with blood cancers. Snowdome has worked with several passionate donors to invest over $750,000 and has successfully secured $311,000 in matched funding through the Victorian Cancer Agency. A wonderful model of ‘government & philanthropy’ … Continued
Since Snowdome began in 2010, we’ve been working hard to attain some significant achievements. With the generous help of our donors and supporters:- – 8 clinical trials have been opened with Snowdome support; – 375 Australian blood cancer patients will be receiving next-generation treatments by 2018; – a joint initiative has been undertaken with the Victorian … Continued
Dr Jake Shortt views haematology and blood cancers as one of the most complex aspects of medicine. He enjoys the intellectual challenge of researching blood cancers and likes to question established dogmas and ‘think outside of the square’. During Dr Shortt’s PhD project, he was using a solvent, N-methyl-2-pyrrolidone (NMP), to administer drugs to myeloma … Continued
In June this year at the European Haematology Association meeting in Italy, Dr Melita Kenealy, project manager of the Victorian Epigenetics Group, presented the first results of her recently led, large Australian study for patients with Myelodysplastic syndromes. Here is a brief summary of her report, “First Analysis ALLG MDS4 Study”:- ‘Making hope real’ for … Continued
We are delighted to report that Dr Jake Shortt (pictured second from left with Snowdome CEO, Miriam Dexter, the Hon. David Davis and Snowdome Director, Nicky Long) has been awarded the Eva and Les Erdi / Snowdome Foundation Fellowship for New Targets in Haematological Malignancies. The announcement was made recently at a Victorian Cancer Agency … Continued